Elekta (OTCMKTS:EKTAY) Stock Rating Upgraded by Zacks Research

Elekta (OTCMKTS:EKTAY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Elekta Trading Up 0.5%

Shares of EKTAY opened at $4.99 on Tuesday. The stock’s fifty day simple moving average is $5.32 and its 200-day simple moving average is $5.86. The firm has a market capitalization of $1.84 billion, a PE ratio of -31.16 and a beta of 1.01. Elekta has a 12-month low of $4.35 and a 12-month high of $6.93. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47.

Elekta (OTCMKTS:EKTAY) last announced its quarterly earnings data on Thursday, May 28th. The company reported $0.06 EPS for the quarter. The firm had revenue of $521.00 million during the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. As a group, research analysts predict that Elekta will post 0.43 earnings per share for the current year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.